Kirkland Represents CF PharmTech on its HK$300 Million H-Share Placing

Kirkland & Ellis represented CF PharmTech, Inc. (CF PharmTech, HKEX: 2652) on its H-share Placing (the H-Share Placing), which was announced on July 31, 2026 and completed on August 6, 2026. The overall coordinators included CLSA Limited and CCB International Capital Limited.

The gross proceeds from the H-Share Placing amounted to approximately HKD 300 million, which will be mainly used for the clinical and pre-clinical development of CF PharmTech’s innovative drug candidates, and the development of its complex inhalation formulation products globally, including CMC studies, clinical studies, delivery device development and registration and regulatory filing expenses.

Kirkland also advised CF PharmTech on its successful IPO in October 2025 and has been serving as its post-listing annual compliance counsel since then.

The Kirkland team included capital markets lawyers Mengyu Lu, George Zheng, Yuchen Han and Jiawei Zhao.